DermBiont lands $28m Series A2
DermBiont, a developer of targeted topical therapeutics that address the root causes of skin diseases, has raised $28 million in Series A2 financing.
DermBiont, a developer of targeted topical therapeutics that address the root causes of skin diseases, has raised $28 million in Series A2 financing.
Copyright PEI Media
Not for publication, email or dissemination